Alembic Pharma gets USFDA nod for generic influenza treatment drug

Alembic Pharmaceuticals has secured USFDA approval for its generic oseltamivir phosphate oral suspension, a key treatment for influenza. This development offers a more accessible option for patients aged two weeks and above suffering from acute, uncomplicated flu. The approval marks a significant step in providing affordable alternatives to the reference drug, Tamiflu, potentially impacting a market valued at an estimated USD 27 million.